Sci Rep 8:110
Survodutide Research# Key trials include the obesity Phase 2 (Lancet Diabetes & Endocrinology, 2024, 18.7% weight loss), MASH Phase 2 (NEJM, 2024, 62% MASH resolution), SYNCHRONIZE-1/2 (Phase 3, obesity, fully enrolled), and LIVERAGE (Phase 3, MASH, ongoing)
Disclose all medications, supplements, prior injection reactions, and any liver or kidney history before starting
This gap underscores the need for more education and research to clarify the role of cannabinoids in glaucoma treatment and to address patient concerns (62)
Larazotide (intestinal health) Article: Larazotide: potential for intestinal health Larazotide is a synthetic peptide that shows promise for strengthening intestinal tight junctions to prevent leaky gut syndrome, reducing passage of toxins, bacteria, and undigested food into the bloodstream that triggers inflammation and autoimmune responses